Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

Song Chu Ko, Akinobu Gotoh, George N. Thalmann, Haiyen E. Zhau, Dennis A. Johnston, Wei Wei Zhang, Chinghai Kao, Leland W K Chung

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The lethal phenotypes of advanced prostate cancer are androgen independent (AI) and metastatic to the axial skeleton. Our laboratory has developed an AI mouse model of metastatic human prostate cancer. In this communication, we report the development of tumor suppressor gene therapy in this AI and metastatic (C4-2) cancer model. By using recombinant adenovirus as a delivery vehicle, we introduced a wild-type p53 tumor suppressor gene into prostate cancer cell lines. Despite a silent mutation at codon 152 of the p53 gene, C4-2 cells express functional, but low, levels of p53 protein. However, the other prostatic cell lines, PC-3 and DU145, have a deletion mutation and two point mutations of the p53 gene, respectively. lit vitro studies showed that cell growth, as measured by the thymidine incorporation assay, was inhibited in the C4-2, PC-3, and DU145 cells infected with wild-type p53 adenovirus in comparison to control viruses. Recombinant wild-type p53 adenovirus inhibited prostate tumor growth and its production of prostate-specific antigen (PSA) when injected into C4-2 tumors in nude mice. All p53-treated mice were tumor free as long as 12 weeks after cessation of the 8-week treatment regimen. Two of 8 p53-treated mice developed small tumors growing at distant sites after a prolonged period of follow-up observation. Moreover, other AI prostate cancer cells, PC-3 and DU145, treated with Ad5-CMV-p53 failed to develop into tumors in vivo. This gene therapy strategy may be used against AI prostatic cancer regardless of p53 gene mutation status.

Original languageEnglish (US)
Pages (from-to)1683-1691
Number of pages9
JournalHuman Gene Therapy
Volume7
Issue number14
StatePublished - Sep 10 1996
Externally publishedYes

Fingerprint

Adenoviridae
Androgens
Prostatic Neoplasms
p53 Genes
Neoplasms
Tumor Suppressor Genes
Genetic Therapy
Castration-Resistant Prostatic Neoplasms
Therapeutics
Cell Line
Sequence Deletion
Prostate-Specific Antigen
Growth
Point Mutation
Nude Mice
Skeleton
Codon
Thymidine
Prostate
Observation

ASJC Scopus subject areas

  • Genetics

Cite this

Ko, S. C., Gotoh, A., Thalmann, G. N., Zhau, H. E., Johnston, D. A., Zhang, W. W., ... Chung, L. W. K. (1996). Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Human Gene Therapy, 7(14), 1683-1691.

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. / Ko, Song Chu; Gotoh, Akinobu; Thalmann, George N.; Zhau, Haiyen E.; Johnston, Dennis A.; Zhang, Wei Wei; Kao, Chinghai; Chung, Leland W K.

In: Human Gene Therapy, Vol. 7, No. 14, 10.09.1996, p. 1683-1691.

Research output: Contribution to journalArticle

Ko, SC, Gotoh, A, Thalmann, GN, Zhau, HE, Johnston, DA, Zhang, WW, Kao, C & Chung, LWK 1996, 'Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model', Human Gene Therapy, vol. 7, no. 14, pp. 1683-1691.
Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Human Gene Therapy. 1996 Sep 10;7(14):1683-1691.
Ko, Song Chu ; Gotoh, Akinobu ; Thalmann, George N. ; Zhau, Haiyen E. ; Johnston, Dennis A. ; Zhang, Wei Wei ; Kao, Chinghai ; Chung, Leland W K. / Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. In: Human Gene Therapy. 1996 ; Vol. 7, No. 14. pp. 1683-1691.
@article{1b96f79ea5bc485f851bbf9c4d3e74d8,
title = "Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model",
abstract = "The lethal phenotypes of advanced prostate cancer are androgen independent (AI) and metastatic to the axial skeleton. Our laboratory has developed an AI mouse model of metastatic human prostate cancer. In this communication, we report the development of tumor suppressor gene therapy in this AI and metastatic (C4-2) cancer model. By using recombinant adenovirus as a delivery vehicle, we introduced a wild-type p53 tumor suppressor gene into prostate cancer cell lines. Despite a silent mutation at codon 152 of the p53 gene, C4-2 cells express functional, but low, levels of p53 protein. However, the other prostatic cell lines, PC-3 and DU145, have a deletion mutation and two point mutations of the p53 gene, respectively. lit vitro studies showed that cell growth, as measured by the thymidine incorporation assay, was inhibited in the C4-2, PC-3, and DU145 cells infected with wild-type p53 adenovirus in comparison to control viruses. Recombinant wild-type p53 adenovirus inhibited prostate tumor growth and its production of prostate-specific antigen (PSA) when injected into C4-2 tumors in nude mice. All p53-treated mice were tumor free as long as 12 weeks after cessation of the 8-week treatment regimen. Two of 8 p53-treated mice developed small tumors growing at distant sites after a prolonged period of follow-up observation. Moreover, other AI prostate cancer cells, PC-3 and DU145, treated with Ad5-CMV-p53 failed to develop into tumors in vivo. This gene therapy strategy may be used against AI prostatic cancer regardless of p53 gene mutation status.",
author = "Ko, {Song Chu} and Akinobu Gotoh and Thalmann, {George N.} and Zhau, {Haiyen E.} and Johnston, {Dennis A.} and Zhang, {Wei Wei} and Chinghai Kao and Chung, {Leland W K}",
year = "1996",
month = "9",
day = "10",
language = "English (US)",
volume = "7",
pages = "1683--1691",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "14",

}

TY - JOUR

T1 - Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

AU - Ko, Song Chu

AU - Gotoh, Akinobu

AU - Thalmann, George N.

AU - Zhau, Haiyen E.

AU - Johnston, Dennis A.

AU - Zhang, Wei Wei

AU - Kao, Chinghai

AU - Chung, Leland W K

PY - 1996/9/10

Y1 - 1996/9/10

N2 - The lethal phenotypes of advanced prostate cancer are androgen independent (AI) and metastatic to the axial skeleton. Our laboratory has developed an AI mouse model of metastatic human prostate cancer. In this communication, we report the development of tumor suppressor gene therapy in this AI and metastatic (C4-2) cancer model. By using recombinant adenovirus as a delivery vehicle, we introduced a wild-type p53 tumor suppressor gene into prostate cancer cell lines. Despite a silent mutation at codon 152 of the p53 gene, C4-2 cells express functional, but low, levels of p53 protein. However, the other prostatic cell lines, PC-3 and DU145, have a deletion mutation and two point mutations of the p53 gene, respectively. lit vitro studies showed that cell growth, as measured by the thymidine incorporation assay, was inhibited in the C4-2, PC-3, and DU145 cells infected with wild-type p53 adenovirus in comparison to control viruses. Recombinant wild-type p53 adenovirus inhibited prostate tumor growth and its production of prostate-specific antigen (PSA) when injected into C4-2 tumors in nude mice. All p53-treated mice were tumor free as long as 12 weeks after cessation of the 8-week treatment regimen. Two of 8 p53-treated mice developed small tumors growing at distant sites after a prolonged period of follow-up observation. Moreover, other AI prostate cancer cells, PC-3 and DU145, treated with Ad5-CMV-p53 failed to develop into tumors in vivo. This gene therapy strategy may be used against AI prostatic cancer regardless of p53 gene mutation status.

AB - The lethal phenotypes of advanced prostate cancer are androgen independent (AI) and metastatic to the axial skeleton. Our laboratory has developed an AI mouse model of metastatic human prostate cancer. In this communication, we report the development of tumor suppressor gene therapy in this AI and metastatic (C4-2) cancer model. By using recombinant adenovirus as a delivery vehicle, we introduced a wild-type p53 tumor suppressor gene into prostate cancer cell lines. Despite a silent mutation at codon 152 of the p53 gene, C4-2 cells express functional, but low, levels of p53 protein. However, the other prostatic cell lines, PC-3 and DU145, have a deletion mutation and two point mutations of the p53 gene, respectively. lit vitro studies showed that cell growth, as measured by the thymidine incorporation assay, was inhibited in the C4-2, PC-3, and DU145 cells infected with wild-type p53 adenovirus in comparison to control viruses. Recombinant wild-type p53 adenovirus inhibited prostate tumor growth and its production of prostate-specific antigen (PSA) when injected into C4-2 tumors in nude mice. All p53-treated mice were tumor free as long as 12 weeks after cessation of the 8-week treatment regimen. Two of 8 p53-treated mice developed small tumors growing at distant sites after a prolonged period of follow-up observation. Moreover, other AI prostate cancer cells, PC-3 and DU145, treated with Ad5-CMV-p53 failed to develop into tumors in vivo. This gene therapy strategy may be used against AI prostatic cancer regardless of p53 gene mutation status.

UR - http://www.scopus.com/inward/record.url?scp=0029818270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818270&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1683

EP - 1691

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 14

ER -